Biotechnology company Amgen Inc (NASDAQ: AMGN) announced on Monday that it presented new data for its first-in-class bispecific T-cell engager, IMDELLTRA (Tarlatamab-dlle), targeting DLL3 in extensive-stage small cell lung cancer (ES-SCLC) during the World Conference on Lung Cancer (WCLC) 2024. Results from the Phase 1b DeLLphi-303 study demonstrated that IMDELLTRA, in combination with PD-L1 inhibitors, serves as an effective first-line maintenance therapy.
Findings highlighted manageable safety and positive survival outcomes from the combination therapy. In the IMDELLTRA and Durvalumab arm, the disease control rate was 62.5%, with a 9-month overall survival of 91.8% and a median progression-free survival of 5.3 months. In the IMDELLTRA and Atezolizumab cohort, a similar disease control rate of 62.5% was noted, with a median duration of disease control at 7.2 months and a 9-month overall survival of 86.7%.
Long-term follow-up data from the DeLLphi-301 Phase 2 study reaffirmed the drug's sustained efficacy and safety in previously treated ES-SCLC patients. The objective response rate was 40% among 100 patients, with a median overall survival of 15.2 months.
Safety profiles indicated treatment-related adverse events, with Durvalumab resulting in 15% dose interruptions and Atezolizumab at 17%. Cytokine Release Syndrome primarily manifested as grade 1-2, while Immune effector cell-associated neurotoxicity syndrome occurred infrequently.
IMDELLTRA, which targets DLL3 on cancer cells and CD3 on T cells, received accelerated FDA approval on 16 May 2024 for patients experiencing disease progression after platinum-based chemotherapy. Ongoing studies will further clarify its efficacy and safety profile in treating this challenging malignancy.
NCI reports IND submission for pilot study of Senhwa Biosciences Inc's developed Pidnarulex
Epitomee Medical's Capsule cleared by FDA for weight management
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Roche's OCREVUS ZUNOVO with Halozyme's ENHANZE drug delivery technology receives FDA approval
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Neuspera Medical names new chief operating officer
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024